Leonard Schleifer
Chief Executive Officer at REGENERON PHARMACEUTICALS, INC.
Net worth: 2 331 M $ as of 2024-03-30
Leonard Schleifer active positions
Companies | Position | Start | End |
---|---|---|---|
REGENERON PHARMACEUTICALS, INC. | Chairman | 2023-06-08 | - |
Chief Executive Officer | 1988-01-07 | - | |
Founder | 1988-01-07 | - | |
President | 1988-01-07 | - | |
Director/Board Member | 1993-12-31 | 2023-06-08 | |
Regeneron Ireland DAC
Regeneron Ireland DAC BiotechnologyHealth Technology Part of Regeneron Pharmaceuticals, Inc., Regeneron Ireland DAC is a leading Irish biotechnology company that uses science to develop new medicines for patients. The private company is located in Ireland. The company successfully manufactures a range of biopharmaceuticals for patients worldwide, including approved therapeutic proteins and those involved in clinical studies. | Chief Executive Officer | 2012-12-31 | - |
Founder | 2012-12-31 | - | |
President | 2012-12-31 | - |
Career history of Leonard Schleifer
Former positions of Leonard Schleifer
Companies | Position | Start | End |
---|---|---|---|
Weill Cornell Medical College | Corporate Officer/Principal | - | - |
Training of Leonard Schleifer
University of Virginia | Doctorate Degree |
Cornell University | Undergraduate Degree |
Statistics
International
United States | 5 |
Ireland | 2 |
Operational
Chief Executive Officer | 2 |
Founder | 2 |
President | 2 |
Sectoral
Consumer Services | 4 |
Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
REGENERON PHARMACEUTICALS, INC. | Health Technology |
Private companies | 1 |
---|---|
Regeneron Ireland DAC
Regeneron Ireland DAC BiotechnologyHealth Technology Part of Regeneron Pharmaceuticals, Inc., Regeneron Ireland DAC is a leading Irish biotechnology company that uses science to develop new medicines for patients. The private company is located in Ireland. The company successfully manufactures a range of biopharmaceuticals for patients worldwide, including approved therapeutic proteins and those involved in clinical studies. | Health Technology |
- Stock Market
- Insiders
- Leonard Schleifer
- Experience